相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Kristin B Highland et al.
Lancet Respiratory Medicine (2021)
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial
Toby M. Maher et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis
Hideaki Tsuji et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2020)
Mixed connective tissue disease: a condition in search of an identity
Marta R. Alves et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Athol U Wells et al.
Lancet Respiratory Medicine (2020)
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Yannick Allanore et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease
F. Romero-Bueno et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients
Carlos Fernandez-Diaz et al.
RHEUMATOLOGY (2020)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Anna-Maria Hoffmann-Vold et al.
LANCET RHEUMATOLOGY (2020)
Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Amber Young et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD
Yasuoki Horiike et al.
RHEUMATOLOGY (2019)
Pulmonary Manifestations of Primary Sjogren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management
Sarthak Gupta et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Joshua J. Solomon et al.
ADVANCES IN THERAPY (2019)
Risk stratification and medical therapy of pulmonary arterial hypertension
Nazzareno Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Kevin K. Brown et al.
RESPIRATORY MEDICINE (2019)
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
Toby M. Maher et al.
BMJ OPEN RESPIRATORY RESEARCH (2019)
Impact of Lung Function Decline on Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF)
M. Kreuter et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Kevin R. Flaherty et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjogren's syndrome
Tomoyuki Kakugawa et al.
RESPIRATORY MEDICINE (2018)
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
Geetabali Sircar et al.
RHEUMATOLOGY (2018)
Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment
You-Jung Ha et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Treatment Algorithms for Systemic Sclerosis According to Experts
Andreu Fernandez-Codina et al.
ARTHRITIS & RHEUMATOLOGY (2018)
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Acute exacerbations of progressive-fibrosing interstitial lung diseases
Martin Kolb et al.
EUROPEAN RESPIRATORY REVIEW (2018)
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis Results of the INJOURNEY Trial
Carlo Vancheri et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort
Carina Mihai et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
Marc Humbert et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
John Gerry Coghlan et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren's Syndrome A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts
Caroline H. Shiboski et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
Sean Gaine et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders et al.
TRIALS (2017)
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis
Nicole S. Goh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
Charlotte Hyldgaard et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Joshua J. Solomon et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Ulrich Costabel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Mixed connective tissue disease
Ragnar Gunnarsson et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2016)
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature
Sebastien Sanges et al.
MEDICINE (2016)
Management of interstitial lung disease associated with connective tissue disease
Stephen C. Mathai et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Management of interstitial lung disease associated with connective tissue disease
Stephen C. Mathai et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis
Jose Felix Restrepo et al.
CLINICAL RHEUMATOLOGY (2015)
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2015)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
N. Galie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease
Hyun Mi Kwon et al.
RHEUMATOLOGY (2015)
Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements
Manuel Ramos-Casals et al.
RHEUMATOLOGY (2015)
Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling
Ada Man et al.
RHEUMATOLOGY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis
Alberto Daniel Rocha-Munoz et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Takashi Ogura et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
J. Gerry Coghlan et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rituximab in severe, treatment-refractory interstitial lung disease
Gregory J. Keir et al.
RESPIROLOGY (2014)
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
Dominique Valeyre et al.
RESPIROLOGY (2014)
Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
Manuel Rubio-Rivas et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
Camille Roubille et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
3Features of usual interstitial pneumonia in patients with primary Sjogren's syndrome compared with idiopathic pulmonary fibrosis
Yasunori Enomoto et al.
RESPIRATORY INVESTIGATION (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Dinesh Khanna et al.
ARTHRITIS AND RHEUMATISM (2013)
Clinical Course, Prognosis, and Causes of Death in Mixed Connective Tissue Disease
Agota Hajas et al.
JOURNAL OF RHEUMATOLOGY (2013)
Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
Aryeh Fischer et al.
JOURNAL OF RHEUMATOLOGY (2013)
Definitions and Diagnosis of Pulmonary Hypertension
Marius M. Hoeper et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prognostic Factors in Interstitial Lung Disease Associated with Primary Sjogren's Syndrome: A Retrospective Analysis of 33 Pathologically-Proven Cases
Yasunori Enomoto et al.
PLOS ONE (2013)
Association between anti-TNF-α therapy and interstitial lung disease
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study
Hironao Hozumi et al.
BMJ OPEN (2013)
Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study
Ragnar Gunnarsson et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
Takahisa Gono et al.
RHEUMATOLOGY (2012)
The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies
Andras Komocsi et al.
RHEUMATOLOGY (2012)
Interstitial Lung Disease in Myositis: Clinical Subsets, Biomarkers, and Treatment
Tsuneyo Mimori et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Rheumatoid Arthritis-Interstitial Lung Disease-associated Mortality
Amy L. Olson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Screening for Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis Clinical Characteristics at Diagnosis and Long-Term Survival
Marc Humbert et al.
ARTHRITIS AND RHEUMATISM (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis
Tim Bongartz et al.
ARTHRITIS AND RHEUMATISM (2010)
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis
Eun Ha Kang et al.
BMC MUSCULOSKELETAL DISORDERS (2010)
Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Identifying Systemic Sclerosis as a Unique Phenotype
Lorinda Chung et al.
CHEST (2010)
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
David Montani et al.
EUROPEAN HEART JOURNAL (2010)
Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis
Yasuhito Hamaguchi
JOURNAL OF DERMATOLOGY (2010)
Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases Impact of Interstitial Lung Disease
Stephen C. Mathai et al.
ARTHRITIS AND RHEUMATISM (2009)
Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?
Eric Hachulla et al.
CHEST (2009)
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases
Takafumi Suda et al.
RESPIRATORY MEDICINE (2009)
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis
V. McLaughlin et al.
RHEUMATOLOGY (2009)
Effects of 1-year treatment with CycNophosphamilde on outcomes at 2 years in scleroderma lung disease
Donald P. Tashkin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Pulmonary complications of polymyositis and dermatomyositis
Mairyarn Fathi et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis
Rosita M. Shah et al.
JOURNAL OF THORACIC IMAGING (2007)
Prognosis of fibrotic interstitial pneumonia - Idiopathic versus collagen vascular disease-related subtypes
Joo Hun Park et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
U. A. Walker et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
Mark H. Williams et al.
EUROPEAN HEART JOURNAL (2006)
Early detection of pulmonary arterial hypertension in systemic sclerosis -: A French nationwide prospective multicenter study
E Hachulla et al.
ARTHRITIS AND RHEUMATISM (2005)
Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis
EH Kang et al.
RHEUMATOLOGY (2005)
Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD)
E Bodolay et al.
RHEUMATOLOGY (2005)
Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis
M Fathi et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis
D Tansey et al.
HISTOPATHOLOGY (2004)
Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis
V Cottin et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement
V Steen et al.
ARTHRITIS AND RHEUMATISM (2003)
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
D Mukerjee et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Interstitial lung disease in polymyositis and dermatomyositis
I Marie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Lymphoid interstitial pneumonia - A narrative review
JJ Swigris et al.
CHEST (2002)
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
D Bouros et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
DB Badesch et al.
ANNALS OF INTERNAL MEDICINE (2000)
分享论文
